Follow the Pundits

Tag: Baker Bros Advisors

Editorial illustration depicting the world's leading hedge fund strategies in 2026, including quantitative investing, activist investing, global market analysis, risk management, and data-driven portfolio management.

Best Hedge Funds 2026: Top Quants, Activists, and High-Return Managers

This article lists some of the most successful hedge funds based on the quality of their management, track record, key strategic focus, risk management, fee structure, and other criteria. Hedge funds follow various strategies to offer investors a compelling, but risky investment alternative. Investing with one requires a high minimum investment and specific wealth profile (high net worth, high-income generation threshold) from accredited investors. Hedge funds charge (approx.) a 2% management and 20% performance fee. The idea or hope is that they are worth it. 

Read entire article

Editorial illustration of scientist-investors analyzing biotech data with glowing tickers MDGL, BGNE, and INCY, representing Baker Bros’ science-driven investing strategy.

Madrigal, BeiGene, and Biotech Alpha: Inside the “Gene-ius” Kingmakers of Baker Bros. 2025

Biotech Jedi at work. Baker Bros’ 2025 victory lap shows how Madrigal, BeiGene, and ruthless conviction turned science into serious alpha.

Read entire article

Baker Bros Are Bullish — Can Kodiak Kill the Bears?

Baker Bros Are Bullish — Can Kodiak Kill the Bears?

When the sharpest biotech investors on the planet deploy $60 million, it’s worth paying attention. Kodiak Sciences is a high-risk, high-reward retinal biotech with late-stage trials, real institutional backing, and binary outcomes ahead. Fun, factual, and unapologetically speculative.

Read entire article

Whimsical illustration of targeted protein degradation: glowing STAT6 protein being tagged with ubiquitin while a proteasome vacuum removes it; Baker Bros figures analyzing the process with excitement; biotech humor meets scientific innovation.

Biotech Investor Extraordinaire Baker Bros Adds to Its Massive Stake in Kymera. Should You Buy In?

Baker Bros — the Warren Buffetts of biotech — just super-sized their Kymera (KYMR) position. With Fast Track designation, jaw-dropping STAT6 trial results, and a pioneering protein-degradation platform, is KYMR becoming the next biotech legend?

Read entire article